论文部分内容阅读
选取我科自2013年1月~2014年6月住院及门诊就诊的2型糖尿病合并颈动脉粥样硬化(IMT>1.0)的64例患者为研究对象,所有患者均在常规降血糖治疗的基础上加用阿托伐他汀20mg/d口服,疗程6个月。比较治疗前后患者血脂、hs-CRP和IMT变化。结果:治疗后血脂、hs-CRP水平下降,IMT较治疗前均明显减小,差异均有统计学意义(P<0.05)。结论:阿托伐他汀可以明显降低2型糖尿病合并颈动脉粥样硬化患者血脂、hs-CRP水平,减少颈动脉内膜中层厚度,值得推广应用。
Sixty-four patients with type 2 diabetes mellitus and carotid atherosclerosis (IMT> 1.0) from January 2013 to June 2014 in our department were enrolled in this study. All patients underwent routine hypoglycemic therapy Addition of atorvastatin 20mg / d oral treatment for 6 months. The changes of serum lipids, hs-CRP and IMT in patients before and after treatment were compared. Results: After treatment, the levels of serum lipids and hs-CRP decreased, and the IMT decreased significantly compared with those before treatment. The differences were statistically significant (P <0.05). Conclusion: Atorvastatin can significantly reduce the level of serum lipids and hs-CRP in type 2 diabetic patients with carotid atherosclerosis and reduce the intima-media thickness of carotid arteries, which is worth popularizing and applying.